Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

somapacitan

- PMLiVE

ViiV and Janssen plan pivotal trials of monthly HIV treatment

Rilpivirine – cabotegravir combination could provide a monthly option

- PMLiVE

Syndax teams with Merck/Pfizer on immuno-oncology combo

Oral cancer drug entinostat to test with avelumab

- PMLiVE

Up in smoke

The side-lining of efficacy in medical cannabis debates

Sanofi reception

Sanofi uses priority review voucher for diabetes combo

LixiLan in race with Xultophy in bid to hit US market first

- PMLiVE

Nucala price far too high for US market, says ICER

Concludes GlaxoSmithKline's new severe asthma therapy is not value for money

- PMLiVE

Less is more: how risk-based monitoring is changing trials

A quality risk management approach is one of the biggest drivers for change in clinical research

- PMLiVE

Novo Nordisk will work with IBM on diabetes care

Development of digital platform to help diabetics and their doctors manage their illness

- PMLiVE

Quintiles wins New Models of Care award at PMEA

Rewarded for its rheumatology project for Pfizer

- PMLiVE

Xalkori set for rapid review in new lung cancer indication

Pfizer could produce first FDA-approved biomarker-driven therapy for ROS1-positive NSCLC

- PMLiVE

Pfizer signs $1bn cancer antibody deal with BioAtla

Aims to overcome one of the limitations of antibody-drug conjugate drugs

- PMLiVE

UK site a casualty as Pfizer reduces pain R&D

Will shut down Granta Park facility in Cambridge with loss of 120 jobs

- PMLiVE

Novo Nordisk says Victoza outperforms SGLT2 inhibitors

Comparesthe GLP-1 agonist to Invokana, Jardiance and Farxiga

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links